MediciNova Inc (MNOV) - Total Liabilities
Based on the latest financial reports, MediciNova Inc (MNOV) has total liabilities worth $3.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MediciNova Inc (MNOV) investment intensity to see how much of total assets are deployed in long-term investments.
MediciNova Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how MediciNova Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see MediciNova Inc asset portfolio.
MediciNova Inc Competitors by Total Liabilities
The table below lists competitors of MediciNova Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Many Peaks Minerals Ltd
AU:MPK
|
Australia | AU$647.45K |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
Turkey | TL17.78 Million |
|
Thryv Holdings Inc
NASDAQ:THRY
|
USA | $480.72 Million |
|
Hennessy Ad
NASDAQ:HNNA
|
USA | $60.52 Million |
|
Ybox Real Estate Ltd
TA:YBOX
|
Israel | ILA999.76 Million |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩7.46 Billion |
|
Columbus Acquisition Corp Ordinary Shares
NASDAQ:COLA
|
USA | $106.25K |
|
Gopeng Bhd
KLSE:2135
|
Malaysia | RM243.67 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down MediciNova Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See MNOV equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MediciNova Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MediciNova Inc (2001–2024)
The table below shows the annual total liabilities of MediciNova Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.37 Million | -13.34% |
| 2023-12-31 | $3.89 Million | -0.54% |
| 2022-12-31 | $3.91 Million | +4.92% |
| 2021-12-31 | $3.73 Million | -8.88% |
| 2020-12-31 | $4.09 Million | -5.06% |
| 2019-12-31 | $4.31 Million | +4.75% |
| 2018-12-31 | $4.12 Million | -13.86% |
| 2017-12-31 | $4.78 Million | -9.55% |
| 2016-12-31 | $5.28 Million | +2.48% |
| 2015-12-31 | $5.15 Million | -2.08% |
| 2014-12-31 | $5.26 Million | +27.73% |
| 2013-12-31 | $4.12 Million | -12.11% |
| 2012-12-31 | $4.69 Million | -35.69% |
| 2011-12-31 | $7.29 Million | -84.89% |
| 2010-12-31 | $48.23 Million | -11.20% |
| 2009-12-31 | $54.31 Million | +2392.15% |
| 2008-12-31 | $2.18 Million | -69.49% |
| 2007-12-31 | $7.14 Million | -32.66% |
| 2006-12-31 | $10.61 Million | +58.69% |
| 2005-12-31 | $6.69 Million | -85.50% |
| 2004-12-31 | $46.10 Million | +4243.16% |
| 2003-12-31 | $1.06 Million | +128.76% |
| 2002-12-31 | $464.00K | +42.77% |
| 2001-12-31 | $325.00K | -- |
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more